[go: up one dir, main page]

Zhang et al., 2019 - Google Patents

Synthesis and Preclinical Evaluation of the Fibrin‐Binding Cyclic Peptide 18F‐iCREKA: Comparison with Its Contrasted Linear Peptide

Zhang et al., 2019

View PDF @Full View
Document ID
9306250817411882857
Author
Zhang Y
Wang L
Yu S
Hu K
Huang S
Li Y
Wu H
Li H
Wang Q
Publication year
Publication venue
Contrast Media & Molecular Imaging

External Links

Snippet

Purpose. Cys‐Arg‐Glu‐Lys‐Ala (CREKA) is a pentapeptide which can target fibrin‐ fibronectin complexes. Our previous study has built a probe called iCREKA which was based on CREKA and has proved the feasibility and specificity of iCREKA by the …
Continue reading at onlinelibrary.wiley.com (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0493—Steroids, e.g. cholesterol, testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Similar Documents

Publication Publication Date Title
Li et al. 64Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor αvβ3 integrin expression
Wang et al. ImmunoPET imaging of multiple myeloma with [68 Ga] Ga-NOTA-Nb1053
Zhang et al. Dual-modality imaging of prostate cancer with a fluorescent and radiogallium-labeled gastrin-releasing peptide receptor antagonist
Galbiati et al. A dimeric FAP-targeting small-molecule radioconjugate with high and prolonged tumor uptake
Qiu et al. Rational design of caspase-responsive smart molecular probe for positron emission tomography imaging of drug-induced apoptosis
Zhang et al. Synthesis and Preclinical Evaluation of the Fibrin‐Binding Cyclic Peptide 18F‐iCREKA: Comparison with Its Contrasted Linear Peptide
Deng et al. Synthesis and evaluation of 64Cu-DOTA-NT-Cy5. 5 as a dual-modality PET/fluorescence probe to image neurotensin receptor-positive tumor
CN108434468A (en) A kind of protein binding partner of radioiodination and its application
Qiu et al. Radiofluorinated smart probes for noninvasive PET imaging of legumain activity in living subjects
Cai et al. Positron emission tomography imaging of platelet-derived growth factor receptor β in colorectal tumor xenograft using zirconium-89 labeled dimeric affibody molecule
D’Alessandria et al. In vivo biokinetic and metabolic characterization of the 68 Ga-labelled α5β1-selective peptidomimetic FR366
Fani et al. Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumors
Ding et al. 86Y-labeled albumin-binding fibroblast activation protein inhibitor for late-time-point cancer diagnosis
Gao et al. Synthesis and assessment of ZD2-(68Ga-NOTA) specific to extradomain B fibronectin in tumor microenvironment for PET imaging of pancreatic cancer
Huang et al. ImmunoPET imaging of Trop2 expression in solid tumors with nanobody tracers
Zhang et al. Noninvasive imaging of tumor PD-L1 expression using [99mTc] Tc-labeled KN035 with SPECT/CT
Lymperis et al. Comparative evaluation of the new GRPR‐antagonist 111In‐SB9 and 111In‐AMBA in prostate cancer models: Implications of in vivo stability
Drake et al. Site-specific radiofluorination of biomolecules with 8-[18F]-fluorooctanoic acid catalyzed by lipoic acid ligase
Han et al. 11C‐Labeled Pictilisib (GDC‐0941) as a Molecular Tracer Targeting Phosphatidylinositol 3‐Kinase (PI3K) for Breast Cancer Imaging
Liu et al. A comparison of [18F] AlF-and 68Ga-labeled dual targeting heterodimer FAPI-RGD in malignant tumor: Preclinical evaluation and pilot clinical PET/CT imaging
Meher et al. Prostate‐Specific Membrane Antigen Targeted StarPEG Nanocarrier for Imaging and Therapy of Prostate Cancer
Warram et al. Biodistribution of P-selectin targeted microbubbles
Song et al. 99mTc‐Labeled LyP‐1 for SPECT Imaging of Triple Negative Breast Cancer
Song et al. Development of a Novel Peptide-Based PET Tracer [68Ga] Ga-DOTA-BP1 for BCMA Detection in Multiple Myeloma
Vaidyanathan et al. N ε-(3-[* I] iodobenzoyl)-Lys5-N α-maleimido-Gly1-GEEEK ([* I] IB-Mal-D-GEEEK): a radioiodinated prosthetic group containing negatively charged D-glutamates for labeling internalizing monoclonal antibodies